In a cohort of 508 patients, individuals with combined reactivity for anti-Ro52/anti-Ro60 and anti-La antibodies had an increased risk of lymphomas, while anti-Ro52 single-positive test results were associated with inflammatory myositis, RA, and SjD [115]. Here, TRIM21 is linked to lymphoma.